Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou've finished your 2.5mg starter pen and moved to 5mg — and now the question sitting in your head is whether staying on 5mg Mounjaro longer is a reasonable choice or a sign something isn't working. The short answer: for many people, 5mg is a productive, well-tolerated dose worth holding for longer than the standard four-week window, and the decision belongs with your prescriber, not with a dose-escalation timetable. These are prescription-only medicines, and any change to your dose should follow a clinical review rather than a schedule you set yourself.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've been on 5mg for a month. Nausea has settled. Your appetite is noticeably smaller. The scale has moved, not dramatically, but in the right direction. And your next prescription review is coming up. A common misconception at this point is that staying put means the treatment isn't working hard enough. It doesn't. Tirzepatide's dose escalation exists partly to manage tolerability, not solely to chase faster results. Some people reach a weight-loss rate at 5mg that their prescriber is entirely satisfied with, and holding there for another four weeks (or longer) is a sound clinical call.
The full picture of how Mounjaro works helps here: as a dual GIP and GLP-1 receptor agonist, tirzepatide reduces appetite and slows gastric emptying. Both effects are present at 5mg. Higher doses tend to amplify them, but that also means more pronounced side effects for some people. If you are tolerating 5mg well and losing weight steadily, your prescriber has good reason to take stock before recommending 7.5mg.
The NHS tirzepatide information page confirms that doses are increased gradually, and that the prescriber leads the timing of each step based on individual response.
Prescribers typically look at weight change over a defined period when deciding whether your current dose is doing its job. NICE's guidance on tirzepatide (TA1026) notes that continuing treatment should be reviewed if weight loss falls below 5% after six months at the highest tolerated dose, but 5mg is rarely the highest tolerated dose, and six months is the long-game benchmark, not the four-week one.
In practice, your prescriber is weighing several things at once: how much weight you've lost since starting, whether side effects are manageable, how close you are to your health goals, and whether your body seems to be responding or has plateaued. The decision about whether to stay on 5mg is therefore personal, and not one that a standard schedule can make for you.
If you genuinely feel ready to move up, say so. If you'd rather hold at a dose that's working without pushing your system further, that's worth saying too. Prescribers are not trying to rush you through the dose ladder. They want the best outcome at the lowest burden to you.
For anyone considering the financial side of longer periods at the same dose, our treatment and cost information gives an honest picture of what a private prescription includes.
A small but real group of people find that moving to 7.5mg brings a return of nausea, vomiting or stomach cramps they thought they'd left behind. If 5mg is genuinely comfortable and effective, that comfort has clinical value. The 5mg dose is where most people first feel the appetite-suppressing effect clearly, and staying on 5mg Mounjaro while your body adapts is a legitimate strategy, not a failure to progress.
The side-effect profile at any dose is dominated by gastrointestinal effects: nausea, loose stools, constipation, indigestion, and sometimes burping or fatigue. These are most noticeable after starting or stepping up, and often ease within one to two weeks. If you're still managing significant side effects four weeks into 5mg, your prescriber needs to know before any upward move is considered. Pushing the dose while you're still symptomatic is not the right call.
If you started your journey at 2.5mg and are thinking about how that lower starting dose compares, staying on the 2.5mg starter dose is covered separately, the dynamics are different because 2.5mg is a tolerability step rather than an active treatment tier.
There is no single correct answer to how long someone should stay on 5mg. Some clinical pathways move people on after four weeks as standard; others extend to eight or twelve weeks if the response is good and the person prefers to hold. How long to stay on 5mg is worth reading if timing is your main question, it covers what evidence and clinical practice suggest.
What matters is that the review actually happens. At nume, a real prescriber reads your update at every repeat, including evidence of your current weight and any changes since the last pen. No automated escalation, no box-ticking. If you want to discuss whether staying put is right for you, or whether there's a clinical reason to move to the 10mg range further down the line, that conversation is part of the service.
Explore all weight-loss treatment options or speak to our prescribers if you'd like a clinical view on where you are in your treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.